

IN THE CLAIMS

Amendments to the Claims:

Please amend claims 16-19 and 49 as follows.

Please cancel claims 33-46.

Please add new claims 53-55.

The following listing of claims will replace all prior versions and listings of claims in the application.

Following amendments, claims 16-19 and 47-55 will be pending in the application.

Listing of Claims:

Claims 1-15 (canceled).

Claim 16: (currently amended) A pharmaceutical composition for administering to a human patient comprising a pharmaceutically acceptable excipient and a an effective amount of human cellular composition comprising apoptotic bodies and/or apoptotic cells and optionally necrotic bodies and/or necrotic cells, wherein said apoptotic bodies and/or apoptotic cells exhibit at least two characteristics comprising DNA fragmentation, surface exposure of phosphatidylserine, or altered mitochondrial membrane permeability and further wherein said cellular composition is suitable for administration to said patient.

Claim 17 (currently amended) The pharmaceutical composition of claim 16 wherein said apoptotic cells and/or bodies necrotic bodies and/or necrotic cells comprise no more than 35 10 weight percent necrotic cells and/or bodies.

Claim 18 (currently amended) The pharmaceutical composition of Claim 16 or 17, wherein said apoptotic bodies and/or cells are derived from the patient's own body comprising a

~~liquid suspension of cellular material, from 10% to 90% of the cellular material being apoptotic bodies and/or apoptotic cells.~~

Claim 19 (currently amended) A unit dosage composition for administration to a human patient, comprising a liquid suspension of cellular material including from about 10,000 to 10,000,000 apoptotic cells and/or apoptotic bodies per kilogram of patient body weight, wherein said apoptotic bodies and/or apoptotic cells exhibit at least two characteristics comprising DNA fragmentation, surface exposure of phosphatidylserine, or altered mitochondrial membrane permeability.

Claims 20-46 (canceled).

Claim 47 (previously presented) The unit dosage composition of Claim 19, wherein the dosage contains from about 500,000 to about 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said patent.

Claim 48 (previously presented) The unit dosage composition of Claim 47, wherein the dosage contains from about 1,500,000 to about 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said patent.

Claim 49 (currently amended) The composition of Claim 16, wherein the cellular composition is apoptotic bodies and/or apoptotic cells are in a liquid suspension which further comprises along with viable cells.

Claim 50 (previously presented) The composition of claim 16, wherein the apoptotic bodies and/or apoptotic cells are derived from extracorporeal treatment of human blood cells.

Claim 51 (previously presented) The composition of Claim 50, wherein the apoptotic bodies and/or apoptotic cells are derived from established cultured cell lines.

Claim 52 (previously presented) The composition of Claim 50, wherein the human blood cells are white blood cells.

Claim 53 (new) A pharmaceutical composition for administering to a human patient comprising a pharmaceutically acceptable excipient and a human cellular composition comprising apoptotic bodies and/or apoptotic cells and optionally necrotic bodies and/or necrotic cells, wherein said apoptotic bodies and/or apoptotic cells exhibit at least two characteristics comprising the binding of Fas ligands to Fas receptors, caspase activation, DNA fragmentation, surface exposure of phosphatidylserine, altered mitochondrial membrane permeability, or release of mitochondrial cytochrome-c.

and further wherein said cellular composition is suitable for administration to said patient.

Claim 54 (new) A unit dosage composition for administration to a human patient, comprising a liquid suspension of cellular material including from about 10,000 to 10,000,000 apoptotic cells and/or apoptotic bodies per kilogram of patient body weight, wherein said apoptotic cells and/or apoptotic bodies exhibit at least two characteristics comprising the binding of Fas ligands to Fas receptors, caspase activation, DNA fragmentation, surface exposure of phosphatidylserine, altered mitochondrial membrane permeability, or release of mitochondrial cytochrome-c.

Claim 55 (new) The pharmaceutical composition of Claim 16 or 17, wherein said the apoptotic bodies and/or cells are derived from an established cell line.